Loading…
Employees: 3,494
Size Jinxin Fertility (1951.HK) is a Hong Kong Health Care company (Medical/Nursing Services) with a market value of $800M, the 647th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$2.33 on 6 Nov 2026.
Performance Over six months the shares fell 2.1%, against +7.8% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue grew 6.5% over the last twelve months (peer median +6.9%); the operating margin is 11.4% (peer median 6.8%).
Valuation It trades at 24.4× forward earnings against a peer median of 18.6× (7th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.2 points below its cost of capital (9.5% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$3.05B | HK$2.87B | HK$3.05B | HK$3.08B | HK$2.75B |
| Revenue growth | — | -6% | -1% | +12% | — |
| Gross profit | HK$1.08B | HK$911M | HK$1.14B | HK$1.25B | HK$970M |
| EBITDA | HK$739M | HK$510M | HK$780M | HK$847M | HK$591M |
| Net income | HK$192M | -HK$1.06B | HK$307M | HK$381M | HK$141M |
| Free cash flow | HK$254M | HK$243M | HK$268M | HK$407M | -HK$527M |
| Capital expenditure | HK$267M | HK$287M | HK$284M | HK$192M | HK$1.12B |
| Total debt | n/a | HK$3.29B | HK$2.89B | HK$3.07B | HK$5.00B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1951.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.8% | +0.1% | 10th highest of 21 |
| 6-month return | -2.1% | +7.8% | 6th lowest of 20 |
| Distance from 52-week high | -12.7% | -21.4% | 4th highest of 21 |
| Revenue growth (TTM) | +6.5% | +6.9% | 10th lowest of 21 |
| Operating margin | 11.4% | 6.8% | 8th highest of 21 |
| Forward P/E | 24.4× | 18.6× | 7th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 18.0% | 9.1% | 5th most demanding of 16 |
| Growth delivered (Del g) | +12.4% | +10.9% | 7th highest of 16 |
| Hurdle (Req g minus delivered) | +5.7 pp | -0.9 pp | 4th most demanding of 16 |
| ROIC minus cost of capital | -7.2 pp | -1.0 pp | 5th lowest of 20 |
| EV / EBITDA | 12.0× | 9.6× | 7th most expensive of 14 |
| Net debt / EBITDA | 3.4× | 0.8× | 5th most indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jinxin Fertility 1951.HK | Hong Kong | $800M | -2% | +7% | 11% | 24.4× | 18.0% | +12.4% |
| Thyrocare Technologies THYROCARE.NS | India | $830M | +5% | +22% | 26% | 35.2× | 27.9% | +10.9% |
| Ginkgo Bioworks DNA | United States | $760M | +26% | -52% | -258% | n/a | n/a | n/a |
| WELL Health Technologies WELL.TO | Canada | $760M | -5% | +39% | 7% | 14.7× | 9.1% | +94.5% |
| HK inno.N 195940.KS | South Korea | $745M | -32% | +7% | 12% | 11.8× | -10.8% | +12.2% |
| Terveystalo Oy TTALO.HE | Finland | $883M | -19% | -8% | 8% | 11.1× | -4.6% | +5.3% |
| BML 4694.T | Japan | $887M | -2% | +4% | 7% | 18.6× | -9.7% | +1.6% |
| GMR Solutions GMRS | United States | $672M | n/a | -4% | 14% | 8.0× | -20.0% | -4.0% |
| Fulgent Genetics FLGT | United States | $653M | +49% | +7% | -36% | n/a | n/a | n/a |
| AdaptHealth AHCO | United States | $1.00B | +8% | -3% | 3% | n/a | 16.3% | +25.2% |
| Nephrocare Health Services NEPHROPLUS.NS | India | $639M | +10% | +33% | 14% | 41.9× | 35.7% | +31.6% |
| Regis Healthcare REG.AX | Australia | $1.05B | -17% | +17% | 4% | 25.1× | 14.6% | +14.4% |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $593M | -4% | -19% | 6% | n/a | 8.8% | +3.2% |
| Novogene 688315.SS | China | $1.16B | +31% | +6% | 7% | 35.7× | 17.1% | +8.2% |
| GoodRx GDRX | United States | $1.20B | +20% | -2% | 12% | 10.4× | 6.8% | +7.7% |
| Nutex Health NUTX | United States | $1.24B | +32% | +7% | 43% | 7.2× | -19.5% | +253.5% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +12% | +20% | 18% | 45.6× | 32.4% | +10.5% |
| Pennant PNTG | United States | $1.27B | +1% | +38% | 6% | 24.0× | 21.1% | +19.4% |
| Strata Critical Medical SRTA | United States | $497M | 0% | +23% | -4% | 67.4× | n/a | n/a |
| Lumexa Imaging LMRI | United States | $1.29B | +29% | +8% | 3% | 18.6× | n/a | n/a |
| OPKO Health OPK | United States | $1.29B | +52% | -11% | -29% | n/a | n/a | n/a |